Literature DB >> 16567000

The contributions of Paul Ehrlich to infectious disease.

Gian Franco Gensini1, Andrea Alberto Conti, Donatella Lippi.   

Abstract

Paul Ehrlich (1854-1915) is nowadays considered a pioneer in a number of medical fields, and in the course of time his role in the establishment and development of disciplines such as histology, immunology, oncology and haematology has been acknowledged. Aim of this historical note is to illustrate, in the area of chemotherapy, the special importance of this brilliant scientist whose 150th anniversary of birth occurred in 2004. Already as a medical student, Ehrlich was obsessed by structural organic chemistry and dyes, and, continually studying these issues, he elaborated his theory regarding the discovery of a "magic bullet", able to specifically destroy tumour cells and micro-organisms. In practice he applied methylene blue to the treatment of malaria patients, following his intuition that such a dye could destroy parasites. However, his culminating achievements in the chemotherapic field, reached even at the expense of his health, were the concept of the one-dose treatment of Helicobacter pylori infection, and the creation of arsphenamine (compound 606, or Salvarsan), the first really effective compound in controlling human syphilis. Within the many and various contributions of Ehrlich to the development of experimental and clinical medicine, a special mention of his experimental studies and clinical applications in the area of chemotherapy is essential, since his achievements in this biomedical area remain a paramount legacy in the history of the therapy of infections.

Entities:  

Mesh:

Year:  2006        PMID: 16567000     DOI: 10.1016/j.jinf.2004.05.022

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  14 in total

1.  Old drugs--new uses.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-11       Impact factor: 4.335

Review 2.  Plasmodium drug targets outside the genetic control of the parasite.

Authors:  David J Sullivan
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

3.  Beneficial network effects of methylene blue in an amnestic model.

Authors:  Penny D Riha; Julio C Rojas; F Gonzalez-Lima
Journal:  Neuroimage       Date:  2010-11-16       Impact factor: 6.556

4.  Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines.

Authors:  Ulana Kotowski; Gregor Heiduschka; Markus Brunner; Boban M Erovic; Helga Martinek; Dietmar Thurnher
Journal:  Oncol Lett       Date:  2012-03-14       Impact factor: 2.967

Review 5.  Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet?

Authors:  Hemendra J Vekaria; Lora Talley Watts; Ai-Ling Lin; Patrick G Sullivan
Journal:  Neurochem Int       Date:  2017-04-07       Impact factor: 3.921

Review 6.  The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize.

Authors:  Fèlix Bosch; Laia Rosich
Journal:  Pharmacology       Date:  2008-08-05       Impact factor: 2.547

7.  Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.

Authors:  Liang Shan; Yuanyi Liu; Paul Wang
Journal:  J Basic Clin Med       Date:  2013

Review 8.  Natural Products That Changed Society.

Authors:  Søren Brøgger Christensen
Journal:  Biomedicines       Date:  2021-04-26

Review 9.  Rescuing mitochondria in traumatic brain injury and intracerebral hemorrhages - A potential therapeutic approach.

Authors:  Meenakshi Ahluwalia; Manish Kumar; Pankaj Ahluwalia; Scott Rahimi; John R Vender; Raghavan P Raju; David C Hess; Babak Baban; Fernando L Vale; Krishnan M Dhandapani; Kumar Vaibhav
Journal:  Neurochem Int       Date:  2021-09-22       Impact factor: 3.921

Review 10.  Targeted toxins in brain tumor therapy.

Authors:  Yan Michael Li; Walter A Hall
Journal:  Toxins (Basel)       Date:  2010-11-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.